HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.hillevax.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2024 | $28.00 → $2.00 | Outperform → Market Perform | Leerink Partners |
| 7/9/2024 | $34.00 → $3.00 | Buy → Hold | Stifel |
| 7/9/2024 | $28.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
| 7/8/2024 | Buy → Neutral | Guggenheim | |
| 7/8/2024 | $24.00 → $5.00 | Overweight → Neutral | JP Morgan |
| 12/13/2023 | $28.00 | Buy | H.C. Wainwright |
Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously
Stifel downgraded HilleVax from Buy to Hold and set a new price target of $3.00 from $34.00 previously
H.C. Wainwright downgraded HilleVax from Buy to Neutral and set a new price target of $2.00 from $28.00 previously
Guggenheim downgraded HilleVax from Buy to Neutral
JP Morgan downgraded HilleVax from Overweight to Neutral and set a new price target of $5.00 from $24.00 previously
H.C. Wainwright initiated coverage of HilleVax with a rating of Buy and set a new price target of $28.00
10-Q - HilleVax, Inc. (0001888012) (Filer)
8-K - HilleVax, Inc. (0001888012) (Filer)
8-K - HilleVax, Inc. (0001888012) (Filer)
8-K - HilleVax, Inc. (0001888012) (Filer)
10-Q - HilleVax, Inc. (0001888012) (Filer)
8-K - HilleVax, Inc. (0001888012) (Filer)
8-K - HilleVax, Inc. (0001888012) (Filer)
8-K - HilleVax, Inc. (0001888012) (Filer)
8-K - HilleVax, Inc. (0001888012) (Filer)
EFFECT - HilleVax, Inc. (0001888012) (Filer)
SC 13G/A - HilleVax, Inc. (0001888012) (Subject)
SC 13G/A - HilleVax, Inc. (0001888012) (Subject)
SC 13G - HilleVax, Inc. (0001888012) (Subject)
SC 13D/A - HilleVax, Inc. (0001888012) (Subject)
SC 13G/A - HilleVax, Inc. (0001888012) (Subject)
SC 13G/A - HilleVax, Inc. (0001888012) (Subject)
SC 13G/A - HilleVax, Inc. (0001888012) (Subject)
SC 13G/A - HilleVax, Inc. (0001888012) (Subject)
SC 13G/A - HilleVax, Inc. (0001888012) (Subject)
SC 13G - HilleVax, Inc. (0001888012) (Subject)
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details:Date: Tuesday, September 6, 2022Time: 1:00 – 2:00 p.m. Eastern Daylight Time (EDT)Moderator: Eric Joseph, Ph.D.HilleVax Participant: Robert Hershberg, M.D., Ph.D.,
4 - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
4/A - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy. Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le
BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "HilleVax has continued to make excellent progress in our HIL-214 program following completion of enrollment of our NEST-IN1 clinical trial in late April 2023. Due to issues relating solely to the logistical complexity of pr
BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "HilleVax has continued to make excellent progress on our HIL-214 program, including the recent completion of enrollment of over 3,000 subjects in our NEST-IN1 clinical trial," said Rob Hershberg, MD, PhD, Chairman and Chief
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Nanette Cocero, Ph.D., MBA, to its Board of Directors, effective May 8, 2023. Dr. Cocero served as the Global President of Pfizer Vaccines during the last four years and is a recognized leader in global healthcare. "I am pleased to welcome Nanette, a highly respected and experienced leader in vaccines, as an independent director to the HilleVax board" said Rob Hershberg, MD, PhD, Chairman and Chief Executive Officer of HilleVax. "Nanette brings extensive experience in development and d
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Results As of September 30, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2024 and highlighted recent progress. Recent Business Highlights In Q3 2024, HilleVax announced that the NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints and that the company would discontinue further develo
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workforce reduction to reduce its operating expenses. The reduction of approximately 41 employees, or approximately 40% of the company's workforce, is intended to preserve cash while maintaining core capabilities as the company explores the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates as well as business development-related activities for these vaccine candidates. About HilleVaxHilleVax is a clinical-stage biopharmaceutical company focused on developing a
The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants The company is exploring the potential for continued development of HIL-214 and HIL-216 in adults BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced topline data results from NEST-IN1. NEST-IN1 is a Phase 2b, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of HIL-214 in infants of approximately 5 months of age at the time of i
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and marketable securities as of December 31, 2023 BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-re
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6th Annual Biotechnology Conference in New York, New York on Wednesday, February 7, 2024 at 2:00 p.m. EST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details: Date: Wednesday, February 7, 2024 Time: 2:00 – 2:25 p.m. Eastern Standard Time (EST)Moderator: Se
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy. Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le
BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and Chengdu Kanghua Biological Products Co., Ltd. (Kangh) (SHE: 300841), a biopharmaceutical company engaged in the research, development, production, and sale of bioproducts, today announced the entry into an exclusive license agreement for rights to Kangh's hexavalent virus-like particle (VLP) vaccine candidate for norovirus, referred to by HilleVax as HIL-216, outside of Greater China. HIL-216 includes VLPs for six of the most common norovirus genotypes, including GI.1, GII.2, GII.3, GII.4, GII.6,
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 8, 2024 at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Presentation details: Date:Monday, January 8, 2024Time:1:30 – 2:10 p.m. Pacific Standard Time (PST)Moderator
HilleVax's (NYSE:HLVX) short percent of float has risen 14.66% since its last report. The company recently reported that it has 1.55 million shares sold short, which is 20.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.63 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is
Leerink Partners analyst David Risinger downgrades HilleVax (NASDAQ:HLVX) from Outperform to Market Perform and lowers the price target from $28 to $2.
Stifel analyst Stephen Willey downgrades HilleVax (NASDAQ:HLVX) from Buy to Hold and lowers the price target from $34 to $3.
HC Wainwright & Co. analyst Matthew Caufield downgrades HilleVax (NASDAQ:HLVX) from Buy to Neutral.
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite moving higher on Monday. The Dow traded down 0.12% to 39,329.47 while the NASDAQ rose 0.27% to 18,401.75. The S&P 500 also rose, gaining, 0.09% to 5,572.23. Check This Out: Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsInformation technology shares jumped by 0.6% on Monday. In trading on Monday, communication services shares fell by 0.9%. Top Headline Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Equities Trading UP
U.S. stocks started the week on a neutral note, with the S&P 500 and Nasdaq 100 indices hovering around the flatline by midday trading in New York. This comes after both indices reached fresh record highs last Friday. Small-cap stocks outperformed their larger counterparts, with the iShares Russell 2000 ETF (NYSE:IWM) gaining 0.8%. Meanwhile, blue-chip stocks of the Dow Jones index dipped slightly by 0.1%. Across the Atlantic, French legislative elections concluded with a surprising victory for a left-wing bloc, though they failed to secure an absolute majority. This news led to a downturn in French stocks on the first trading day post-election, as investors worried about potential tax
Shares of Arhaus, Inc. (NASDAQ:ARHS) fell sharply during Monday's session. Jefferies analyst Jonathan Matuszewski downgraded Arhaus from Buy to Hold and lowered the price target from $22 to $16. Arhaus shares dipped 7.9% to $14.55 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Morphic Holding, Inc. (NASDAQ:MORF) shares jumped 75% to $55.72 after Eli Lilly agreed to buy the company for $57 per share in cash. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) climbed 71% to $6.97 after jumping around 50% on Friday. SRIVARU Holding Limited (NASDAQ:SVMH) shares climbed 61.3% to $0.2549 after the company announced the deployment of advanced
Guggenheim analyst Seamus Fernandez downgrades HilleVax (NASDAQ:HLVX) from Buy to Neutral.
U.S. stocks traded mixed midway through trading, with the Dow Jones index turning lower on Monday. The Dow traded down 0.19% to 39,301.00 while the NASDAQ rose 0.21% to 18,390.4. The S&P 500 also fell, dropping, 0.02% to 5,566.26. Check This Out: Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsMaterials shares jumped by 0.4% on Monday. In trading on Monday, communication services shares fell by 1.1%. Top Headline Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Equities Trading UP Mor
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Monday. Following the market opening Monday, the Dow traded up 0.57% to 39,599.54 while the NASDAQ rose 0.09% to 18,368.86. The S&P 500 also rose, gaining, 0.19% to 5,577.53. Check This Out: Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsIndustrials shares jumped by 0.7% on Monday. In trading on Monday, materials shares fell by 0.7%. Top Headline Shares of The Greenbrier Companies, Inc. (NYSE:GBX) fell around 6% on Monday after the company reported worse-than-expected third-quarter financial results. Greenbrier posted